Cheng Du Sheng Nuo Biotec Co. Ltd. A (688117) - Total Liabilities

Latest as of September 2025: CN¥877.24 Million CNY ≈ $128.37 Million USD

Based on the latest financial reports, Cheng Du Sheng Nuo Biotec Co. Ltd. A (688117) has total liabilities worth CN¥877.24 Million CNY (≈ $128.37 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check 688117 asset liquidity ratio to evaluate the company's liquid asset resilience ratio.

Cheng Du Sheng Nuo Biotec Co. Ltd. A - Total Liabilities Trend (2017–2024)

This chart illustrates how Cheng Du Sheng Nuo Biotec Co. Ltd. A's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see Cheng Du Sheng Nuo Biotec Co. Ltd. A total assets.

Cheng Du Sheng Nuo Biotec Co. Ltd. A Competitors by Total Liabilities

The table below lists competitors of Cheng Du Sheng Nuo Biotec Co. Ltd. A ranked by their total liabilities.

Company Country Total Liabilities
WIA Gold Ltd
AU:WIA
Australia AU$1.23 Million
Suzhou Alton Electrical & Mechanical Industry Co. Ltd.
SHE:301187
China CN¥2.75 Billion
Gallant Precision Machining Co Ltd
TWO:5443
Taiwan NT$7.62 Billion
Soulbrain Holdings Co. Ltd
KQ:036830
Korea ₩710.86 Billion
Vulcan Steel Ltd
AU:VSL
Australia AU$787.93 Million
Guangdong Eastone Century Technology Co Ltd
SHE:300310
China CN¥1.23 Billion
Beijing Scitop Bio Tech Co Ltd
SHE:300858
China CN¥236.16 Million
Guaranty Bancshares, Inc.
NYSE:GNTY
USA $2.81 Billion

Liability Composition Analysis (2017–2024)

This chart breaks down Cheng Du Sheng Nuo Biotec Co. Ltd. A's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See debt-free asset ratio of Cheng Du Sheng Nuo Biotec Co. Ltd. A to measure how much of total assets are equity-financed.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric Value Description
Current Ratio 1.46 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity 0.85 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 0.46 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Cheng Du Sheng Nuo Biotec Co. Ltd. A's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Cheng Du Sheng Nuo Biotec Co. Ltd. A (2017–2024)

The table below shows the annual total liabilities of Cheng Du Sheng Nuo Biotec Co. Ltd. A from 2017 to 2024.

Year Total Liabilities Change
2024-12-31 CN¥729.58 Million
≈ $106.76 Million
+67.48%
2023-12-31 CN¥435.63 Million
≈ $63.75 Million
+54.88%
2022-12-31 CN¥281.27 Million
≈ $41.16 Million
+64.03%
2021-12-31 CN¥171.48 Million
≈ $25.09 Million
+10.34%
2020-12-31 CN¥155.41 Million
≈ $22.74 Million
+9.09%
2019-12-31 CN¥142.46 Million
≈ $20.85 Million
-5.59%
2018-12-31 CN¥150.90 Million
≈ $22.08 Million
+41.74%
2017-12-31 CN¥106.46 Million
≈ $15.58 Million
--

About Cheng Du Sheng Nuo Biotec Co. Ltd. A

SHG:688117 China Drug Manufacturers - Specialty & Generic
Market Cap
$553.88 Million
CN¥3.79 Billion CNY
Market Cap Rank
#11823 Global
#3391 in China
Share Price
CN¥24.05
Change (1 day)
+1.35%
52-Week Range
CN¥21.44 - CN¥46.10
All Time High
CN¥48.78
About

ChengDu ShengNuo Biotec Co.,Ltd. engages in the research and development, production, sale, and export of peptide drugs. The company offers semaglutide, tirzepatide, retatrutide, cagrilintide, lanreotide, bivalirudin, epitifibatide, liraglutide; icatibant, octreotide, teriparatide, ziconotide, ganirelix, linaclotide, abaloparatide, terlipressin acetate; levosimendane, thymosin alpha, enfuvirtide,… Read more